Mignar 50 mg is an oral alpha-glucosidase inhibitor, a unique class of anti-diabetic drugs used in patients with Type 2 diabetes. It effectively reduces postprandial glucose concentrations and the sharp peaks commonly associated with ingestion of a meal. Miglitol, the active substance in medicine, delays the digestion of ingested carbohydrates, resulting in a rise in blood glucose concentration following meals. Administration of Mignar 30 minutes before a meal can effectively prevent hyperinsulinemic hypoglycemia (the condition and effects of low blood glucose caused by excessive insulin. In diabetic patients, alpha-glucosidase inhibitors result in delayed absorption and lowering of postprandial hyperglycaemic (an exaggerated increase in blood sugar following a meal). Miglitol is combined with diet and exercise to control blood sugar in adults with type 2 diabetes.

There is no fixed dosage regimen for managing diabetes mellitus with Mignar tablets or any other anti-diabetic drug. The dose must be individualized depending on effectiveness and tolerance while not exceeding the recommended dosage of 100 mg Miglitol thrice a day. The anti-diabetic drug should be used three times a day at the start of the meal. The therapeutic goal is to reduce blood sugar levels by using the lowest effective dose of Miglitol, either as monotherapy or in combination with a sulfonylurea.

Because Mignar tablets are excreted primarily by the kidneys, accumulation of Miglitol is expected in patients with kidney disease. Therefore, treatment of these patients with an alpha-glucosidase inhibitor like Miglitol is not recommended.

Miglitol 50 is contraindicated in patients with:

• Hypersensitivity to the anti-diabetic agent or any of its components
• Colonic ulceration, inflammatory bowel disease, or partial intestinal obstruction, and in patients predisposed to intestinal obstruction.
• Diabetic ketoacidosis
• Chronic intestinal diseases are associated with digestion issues or problems or conditions that may worsen due to increased gas formation in the stomach.

Gastrointestinal symptoms are the most common reaction to Mignar 50 mg. Side effects such as abdominal pain, diarrhoea, and flatulence were reported in patients treated with Miglitol. Abdominal pain and diarrhoea tended to resolve with continued treatment. 

Skin rash was reported in some patients. Rashes were also reported and considered generally transient, and most were assessed as unrelated to Miglitol by clinical experts.